| Host: |
Rabbit |
| Applications: |
WB |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-MARCH8 (232-291) is suitable for use in Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:500-1:2000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
MARCHF8 |
| Gene ID: |
220972 |
| Uniprot ID: |
MARH8_HUMAN |
| Immunogen Region: |
232-291 |
| Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 232-291 of human MARCH8 (NP_659458.2). |
| Immunogen Sequence: |
YNRVIYVQNCPETSKKNIFE KSPLTEPNFENKHGYGICHS DTNSSCCTEPEDTGAEIIHV |
| Tissue Specificity | Broadly expressed. Present in immature dendritic cells (at protein level). |
| Function | E3 ubiquitin-protein ligase that plays several important roles in innate immunity and adaptive immunity. Mediates ubiquitination of CD86 and MHC class II proteins, such as HLA-DR alpha and beta, and promotes their subsequent endocytosis and sorting to lysosomes via multivesicular bodies. Possesses a very broad antiviral activity by specifically inactivating different viral fusion proteins. Targets and ubiquitinates cytoplasmic lysine residues of viral envelope glycoproteins with single transmembrane domains leading to their lysosomal degradation. Therefore, shows broad-spectrum inhibition against many viruses including retroviruses, rhabdoviruses, arenaviruses, sarbecoviruses or influenzaviruses. Strongly blocks human immunodeficiency virus type 1 envelope glycoprotein incorporation into virions by down-regulating its cell surface expression. Blocks also ebola virus glycoprotein/GP incorporation via surface down-regulation. Mediates 'Lys-63'-linked polyubiquitination of influenza M2 to target it to lysosome for degradation. Mediates the regulation of constitutive ubiquitination and trafficking of the viral restriction factor BST2 within the endocytic pathway. Plays a role in maintenance of immune tolerance to self by promoting the turnover and proteasomal degradation of PD-L1/CD274 via ubiquitination. Catalyzes the 'Lys-63'-linked polyubiquitylation of cGAS thereby inhibiting its DNA binding ability and impairing its antiviral innate immunity. (Microbial infection) Mediates 'Lys-63'-linked polyubiquitination of hepatitis C virus/HCV protein NS2 which allows its binding to HGS, an ESCRT-0 complex component, and this interaction is essential for HCV envelopment. |
| Protein Name | E3 Ubiquitin-Protein Ligase Marchf8Cellular Modulator Of Immune RecognitionC-MirMembrane-Associated Ring Finger Protein 8Membrane-Associated Ring-Ch Protein ViiiMarch-ViiiRing Finger Protein 178Ring-Type E3 Ubiquitin Transferase Marchf8 |
| Cellular Localisation | Golgi Apparatus MembraneEndoplasmic Reticulum MembraneCytoplasmic Vesicle MembraneMulti-Pass Membrane ProteinLysosome MembraneEarly Endosome Membrane |
| Alternative Antibody Names | Anti-E3 Ubiquitin-Protein Ligase Marchf8 antibodyAnti-Cellular Modulator Of Immune Recognition antibodyAnti-C-Mir antibodyAnti-Membrane-Associated Ring Finger Protein 8 antibodyAnti-Membrane-Associated Ring-Ch Protein Viii antibodyAnti-March-Viii antibodyAnti-Ring Finger Protein 178 antibodyAnti-Ring-Type E3 Ubiquitin Transferase Marchf8 antibodyAnti-MARCHF8 antibodyAnti-MARCH8 antibodyAnti-MIR antibodyAnti-RNF178 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
